These lawsuits assert legal theories, including: Trademark infringement Violating the corporate practice of medicine doctrine False advertising Unfair competition Violations of federal drug laws (misbranding, unapproved new drugs) FDA Enforcement On February 6, 2026, FDA announced its intent to use all available compliance and enforcement tools within its authorities to address unsubstantiated claims and associated public health concerns. The FDA explicitly announced steps to combat compounding pharmacies making these marketing claims: Compounded products are generic versions of FDA-approved drugs Compounded products are the same as FDA-approved drugs Compounded products use the same active ingredient as FDA-approved drugs Compounded products are clinically proven to produce results FDA has made clear that failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction. This means the agency may bypass traditional warning letter procedures
Every patient receives a pre-therapy clinical assessment and where indicated, advanced biomarker testing that identifies their specific biological ageing priorities
[126] demonstrated in a drug clinical study in 2018 that GLP-/GIP dual agonists could significantly reduce TG and TC levels in patients compared with placebo
it performs best when complemented by the right diet and, where possible, regular activity
The microdosing GLP-1 guide discusses this concept in broader context
